|
1
|
Giraldi L, Leoncini E, Pastorino R,
Wünsch-Filho V, de Carvalho M, Lopez R, Cadoni G, Arzani D,
Petrelli L, Matsuo K, et al: Alcohol and cigarette consumption
predict mortality in patients with head and neck cancer: A pooled
analysis within the International Head and Neck Cancer Epidemiology
(INHANCE) Consortium. Ann Oncol. 28:2843–2851. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kawakita D, Lee YA, Turati F, Parpinel M,
Decarli A, Serraino D, Matsuo K, Olshan AF, Zevallos JP, Winn DM,
et al: Dietary fiber intake and head and neck cancer risk: A pooled
analysis in the International Head and Neck Cancer Epidemiology
consortium. Int J Cancer. 141:1811–1821. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pulte D and Brenner H: Changes in survival
in head and neck cancers in the late 20th and early 21st century: A
period analysis. Oncologist. 15:994–1001. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cohen EEW, Licitra LF, Burtness B, Fayette
J, Gauler T, Clement PM, Grau JJ, Del Campo JM, Mailliez A, Haddad
RI, et al: Biomarkers predict enhanced clinical outcomes with
afatinib versus methotrexate in patients with second-line recurrent
and/or metastatic head and neck cancer. Ann Oncol. 28:2526–2532.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Dong H, Zhu G, Tamada K and Chen L: B7-H1,
a third member of the B7 family, co-stimulates T-cell proliferation
and interleukin-10 secretion. Nat Med. 5:1365–1369. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hirano F, Kaneko K, Tamura H, Dong H, Wang
S, Ichikawa M, Rietz C, Flies DB, Lau JS, Zhu G, et al: Blockade of
B7-H1 and PD-1 by monoclonal antibodies potentiates cancer
therapeutic immunity. Cancer Res. 65:1089–1096. 2005.PubMed/NCBI
|
|
7
|
Xia Y, Jeffrey Medeiros L and Young KH:
Signaling pathway and dysregulation of PD1 and its ligands in
lymphoid malignancies. Biochim Biophys Acta. 1865:58–71.
2016.PubMed/NCBI
|
|
8
|
Rollins MR and Gibbons JR: CD80 expressed
by CD8+ T cells contributes to PD-L1-induced apoptosis
of activated CD8+ T cells. J Immunol Res.
2017:76594622017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zandberg DP and Strome SE: The role of the
PD-L1: PD-1 pathway in squamous cell carcinoma of the head and
neck. Oral Oncol. 50:627–632. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Topalian SL, Drake CG and Pardoll DM:
Immune checkpoint blockade: A common denominator approach to cancer
therapy. Cancer Cell. 27:450–461. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Topalian SL, Drake CG and Pardoll DM:
Targeting the PD-1/B7-H1(PD-L1) pathway to activate antitumor
immunity. Curr Opin Immunol. 24:207–212. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Clark CA, Gupta HB, Sareddy G, Pandeswara
S, Lao S, Yuan B, Drerup JM, Padron A, Conejo-Garcia J, Murthy K,
et al: Tumor-intrinsic PD-L1 signals regulate cell growth,
pathogenesis, and autophagy in ovarian cancer and melanoma. Cancer
Res. 76:6964–6974. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Alsuliman A, Colak D, Al-Harazi O, Fitwi
H, Tulbah A, Al-Tweigeri T, Al-Alwan M and Ghebeh H: Bidirectional
crosstalk between PD-L1 expression and epithelial to mesenchymal
transition: Significance in claudin-low breast cancer cells. Mol
Cancer. 14:1492015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cao Y, Zhang L, Kamimura Y, Ritprajak P,
Hashiguchi M, Hirose S and Azuma M: B7-H1 overexpression regulates
epithelial-mesenchymal transition and accelerates carcinogenesis in
skin. Cancer Res. 71:1235–1243. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Fang X, Chen C, Xia F, Yu Z, Zhang Y,
Zhang F, Gu H, Wan J, Zhang X, Weng W, et al: CD274 promotes cell
cycle entry of leukemia-initiating cells through JNK/Cyclin D2
signaling. J Hematol Oncol. 9:1242016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ghebeh H, Tulbah A, Mohammed S, Elkum N,
Bin Amer SM, Al-Tweigeri T and Dermime S: Expression of B7-H1 in
breast cancer patients is strongly associated with high
proliferative Ki-67-expressing tumor cells. Int J Cancer.
121:751–758. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Shi SJ, Wang LJ, Wang GD, Guo ZY, Wei M,
Meng YL, Yang AG and Wen WH: B7-H1 expression is associated with
poor prognosis in colorectal arcinoma and regulates the
proliferation and invasion of HCT116 colorectal cancer cells. PLoS
One. 8:e760122013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2−ΔΔCT method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chamoto K, Al-Habsi M and Honjo T: Role of
PD-1 in immunity and diseases. Curr Top Microbiol Immunol.
410:75–97. 2017.PubMed/NCBI
|
|
20
|
Nishimura H, Nose M, Hiai H, Minato N and
Honjo T: Development of lupus-like autoimmune diseases by
disruption of the PD-1 gene encoding an ITIM motif-carrying
immunoreceptor. Immunity. 11:141–151. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Dong H, Strome SE, Salomao DR, Tamura H,
Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K, et al:
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential
mechanism of immune evasion. Nat Med. 8:793–800. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Boussiotis VA: Molecular and biochemical
aspects of the PD-1 checkpoint pathway. N Engl J Med.
375:1767–1778. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Topalian SL, Hodi FS, Brahmer JR,
Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD,
Sosman JA, Atkins MB, et al: Safety, activity, and immune
correlates of anti-PD-1 antibody in cancer. N Engl J Med.
366:2443–2454. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ,
Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, et al:
Safety and activity of anti-PD-L1 antibody in patients with
advanced cancer. N Engl J Med. 366:2455–2465. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Baumeister SH, Freeman GJ, Dranoff G and
Sharpe AH: Coinhibitory pathways in immunotherapy for cancer. Annu
Rev Immunol. 34:539–573. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ahmad SM, Borch TH, Hansen M and Andersen
MH: PD-L1-specific T cells. Cancer Immunol Immunother. 65:797–804.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kleffel S, Posch C, Barthel SR, Mueller H,
Schlapbach C, Guenova E, Elco CP, Lee N, Juneja VR, Zhan Q, et al:
Melanoma cell-intrinsic PD-1 receptor functions promote tumor
growth. Cell. 162:1242–1256. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chen L, Gibbons DL, Goswami S, Cortez MA,
Ahn YH, Byers LA, Zhang X, Yi X, Dwyer D, Lin W, et al: Metastasis
is regulated via microRNA-200/ZEB1 axis control of tumour cell
PD-L1 expression and intratumoral immunosuppression. Nat Commun.
5:52412014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Mak MP, Pan T, Diao L, Cardnell RJ,
Gibbons DL, William WN, Skoulidis F, Parra ER, Rodriguez-Canales J,
Wistuba II, et al: A patient-derived, pan-cancer EMT signature
identifies global molecular alterations and immune target
enrichment following epithelial to mesenchymal transition. Clin
Cancer Res. 22:609–620. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ritprajak P and Azuma M: Intrinsic and
extrinsic control of expression of the immunoregulatory molecule
PD-L1 in epithelial cells and squamous cell carcinoma. Oral Oncol.
51:221–228. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Strome SE, Dong H, Tamura H, Voss SG,
Flies DB, Tamada K, Salomao D, Cheville J, Hirano F, Lin W, et al:
B7-H1 blockade augments adoptive T-cell immunotherapy for squamous
cell carcinoma. Cancer Res. 63:6501–6505. 2003.PubMed/NCBI
|
|
32
|
Hsu MC, Hsiao JR, Chang KC, Wu YH, Su IJ,
Jin YT and Chang Y: Increase of programmed death-1-expressing
intratumoral CD8 T cells predicts a poor prognosis for
nasopharyngeal carcinoma. Mod Pathol. 23:1393–1403. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Muenst S, Schaerli AR, Gao F, Däster S,
Trella E, Droeser RA, Muraro MG, Zajac P, Zanetti R, Gillanders WE,
et al: Expression of programmed death ligand 1 (PD-L1) is
associated with poor prognosis in human breast cancer. Breast
Cancer Res Treat. 146:15–24. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chang CH, Qiu J, O'Sullivan D, Buck MD,
Noguchi T, Curtis JD, Chen Q, Gindin M, Gubin MM, van der Windt GJ,
et al: Metabolic competition in the tumor microenvironment is a
driver of cancer progression. Cell. 162:1229–1241. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Francisco LM, Salinas VH, Brown KE,
Vanguri VK, Freeman GJ, Kuchroo VK and Sharpe AH: PD-L1 regulates
the development, maintenance, and function of induced regulatory T
cells. J Exp Med. 206:3015–3029. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Follo MY, Manzoli L, Poli A, McCubrey JA
and Cocco L: PLC and PI3K/Akt/mTOR signalling in disease and
cancer. Adv Biol Regul. 57:10–16. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Jhanwar-Uniyal M, Amin AG, Cooper JB, Das
K, Schmidt MH and Murali R: Discrete signaling mechanisms of mTORC1
and mTORC2: Connected yet apart in cellular and molecular aspects.
Adv Biol Regul. 64:39–48. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Hermida MA, Dinesh Kumar J and Leslie NR:
GSK3 and its interactions with the PI3K/AKT/mTOR signalling
network. Adv Biol Regul. 65:5–15. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Bertacchini J, Frasson C, Chiarini F,
D'Avella D, Accordi B, Anselmi L, Barozzi P, Forghieri F, Luppi M,
Martelli AM, et al: Dual inhibition of PI3K/mTOR signaling in
chemoresistant AML primary cells. Adv Biol Regul. 68:2–9. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Thedieck K, Holzwarth B, Prentzell MT,
Boehlke C, Kläsener K, Ruf S, Sonntag AG, Maerz L, Grellscheid SN,
Kremmer E, et al: Inhibition of mTORC1 by astrin and stress
granules prevents apoptosis in cancer cells. Cell. 154:859–874.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Liu P, Gan W, Inuzuka H, Lazorchak AS, Gao
D, Arojo O, Liu D, Wan L, Zhai B, Yu Y, et al: Sin1 phosphorylation
impairs mTORC2 complex integrity and inhibits downstream Akt
signalling to suppress tumorigenesis. Nat Cell Biol. 15:1340–1350.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Herbst RS, Soria JC, Kowanetz M, Fine GD,
Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger
SN, et al: Predictive correlates of response to the anti-PD-L1
antibody MPDL3280A in cancer patients. Nature. 515:563–567. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Stewart R, Morrow M, Hammond SA, Mulgrew
K, Marcus D, Poon E, Watkins A, Mullins S, Chodorge M, Andrews J,
et al: Identification and characterization of MEDI4736, an
antagonistic anti-PD-L1 monoclonal antibody. Cancer Immunol Res.
3:1052–1062. 2015. View Article : Google Scholar : PubMed/NCBI
|
